B. Riley Wealth Advisors Inc. Buys Shares of 2,289 Cencora, Inc. $COR

B. Riley Wealth Advisors Inc. purchased a new stake in Cencora, Inc. (NYSE:COR) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 2,289 shares of the company’s stock, valued at approximately $686,000.

A number of other hedge funds and other institutional investors have also modified their holdings of COR. Kovitz Investment Group Partners LLC lifted its holdings in shares of Cencora by 9.3% in the first quarter. Kovitz Investment Group Partners LLC now owns 3,513 shares of the company’s stock valued at $977,000 after buying an additional 299 shares during the period. Aptus Capital Advisors LLC lifted its position in shares of Cencora by 39.7% in the 1st quarter. Aptus Capital Advisors LLC now owns 3,699 shares of the company’s stock valued at $1,029,000 after acquiring an additional 1,052 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S lifted its holdings in shares of Cencora by 1,169.0% in the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 93,283 shares of the company’s stock valued at $25,941,000 after purchasing an additional 85,932 shares in the last quarter. Credit Agricole S A boosted its position in Cencora by 23.1% during the 1st quarter. Credit Agricole S A now owns 99,143 shares of the company’s stock worth $27,571,000 after acquiring an additional 18,578 shares during the period. Finally, Carmignac Gestion grew its position in Cencora by 10.2% during the first quarter. Carmignac Gestion now owns 1,103,479 shares of the company’s stock valued at $306,863,000 after purchasing an additional 101,978 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Insider Activity at Cencora

In other news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction on Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the sale, the chief executive officer owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. This trade represents a 11.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 15,290 shares of company stock valued at $5,012,227 over the last 90 days. 10.80% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently commented on COR. Robert W. Baird set a $392.00 price objective on Cencora in a report on Tuesday. Wells Fargo & Company upped their price target on Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. JPMorgan Chase & Co. lifted their target price on Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. TD Cowen increased their price objective on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Finally, Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and a consensus price target of $373.25.

Cencora Price Performance

Shares of COR stock opened at $341.63 on Wednesday. Cencora, Inc. has a 12-month low of $223.92 and a 12-month high of $377.54. The firm has a fifty day moving average of $344.85 and a 200-day moving average of $312.26. The firm has a market capitalization of $66.27 billion, a price-to-earnings ratio of 42.97, a price-to-earnings-growth ratio of 1.66 and a beta of 0.63. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. The firm had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period in the prior year, the business earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, equities research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, November 14th. Cencora’s dividend payout ratio (DPR) is 30.19%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.